Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Paleo Faliro – page 32

1 033 clinical trials in Paleo Faliro, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Paleo Faliro at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Paleo Faliro

Open in trial search

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Amgen Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Staphylococcal bacteraemia

Not yet recruiting

Safety and Efficacy of Ceftobiprole Medocaril Sodium in Children with Staphylococcus aureus Bacteremia Including Right‑Sided Infective Endocarditis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Ceftobiprole medocaril sodium
  • Sponsor:Istx LLC

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Not yet recruiting

A Phase 3 Trial of BL-M14D1 and Atezolizumab vs Standard Therapy in First‑Line Extensive‑Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Systimmune Inc.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Paleo Faliro

What the registry says about research in the country

01 Respiratory Medicine

Extensive research focusing on chronic respiratory conditions, particularly investigating new therapeutic approaches for asthma and COPD management.

  • Severe Asthma Treatment Studies
  • COPD Exacerbation Prevention
  • Triple Therapy Combinations

Multiple trials evaluating innovative inhaler medications and biological treatments to improve lung function and reduce disease progression.

02 Metabolic Disorders

Comprehensive studies examining treatments for Type 1 and Type 2 Diabetes, with particular attention to weight management and cardiovascular outcomes.

  • Diabetes Management
  • Obesity Treatment
  • Mixed Dyslipidemia

Innovative therapies being tested to improve glycemic control and address related metabolic conditions.

03 Cardiovascular Research

Critical investigations into heart failure prevention and cardiovascular risk reduction, particularly in patients with multiple comorbidities.

  • Heart Failure Prevention
  • Cardiovascular Outcomes
  • Combined Therapy Approaches

Studies evaluating novel drug combinations and their impact on cardiovascular safety and disease progression.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.